BridgeBio Pharma Inc (NASDAQ: BBIO) kicked off on Friday, up 0.96% from the previous trading day, before settling in for the closing price of $35.96. Over the past 52 weeks, BBIO has traded in a range of $21.62-$39.47.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 574.82% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded -28.21%. With a float of $155.16 million, this company’s outstanding shares have now reached $190.04 million.
In an organization with 730 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 97.67%, operating margin of -265.69%, and the pretax margin is -244.34%.
BridgeBio Pharma Inc (BBIO) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of BridgeBio Pharma Inc is 18.28%, while institutional ownership is 76.80%. The most recent insider transaction that took place on Apr 22 ’25, was worth 2,558,025. In this transaction Chief Executive Officer of this company sold 75,000 shares at a rate of $34.11, taking the stock ownership to the 4,873,447 shares. Before that another transaction happened on Apr 14 ’25, when Company’s Director sold 10,000 for $35.00, making the entire transaction worth $350,000. This insider now owns 12,000 shares in total.
BridgeBio Pharma Inc (BBIO) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -28.21% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 59.65% during the next five years compared to -3.04% drop over the previous five years of trading.
BridgeBio Pharma Inc (NASDAQ: BBIO) Trading Performance Indicators
Take a look at BridgeBio Pharma Inc’s (BBIO) current performance indicators. Last quarter, stock had a quick ratio of 4.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 31.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.85, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -2.63 in one year’s time.
Technical Analysis of BridgeBio Pharma Inc (BBIO)
Let’s dig in a bit further. During the last 5-days, its volume was 1.87 million. That was inferior than the volume of 2.95 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 93.49%. Additionally, its Average True Range was 1.78.
During the past 100 days, BridgeBio Pharma Inc’s (BBIO) raw stochastic average was set at 77.60%, which indicates a significant decrease from 99.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.21% in the past 14 days, which was lower than the 58.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $34.02, while its 200-day Moving Average is $29.05. However, in the short run, BridgeBio Pharma Inc’s stock first resistance to watch stands at $36.73. Second resistance stands at $37.15. The third major resistance level sits at $37.95. If the price goes on to break the first support level at $35.51, it is likely to go to the next support level at $34.71. Assuming the price breaks the second support level, the third support level stands at $34.29.
BridgeBio Pharma Inc (NASDAQ: BBIO) Key Stats
The company with the Market Capitalisation of 6.89 billion has total of 189,856K Shares Outstanding. Its annual sales at the moment are 221,900 K in contrast with the sum of -535,760 K annual income. Company’s last quarter sales were recorded 5,880 K and last quarter income was -265,050 K.
